Therapeutic use of compounds
A compound having the formula (I) R1-COOH wherein R1 is an alkyl or alkenyl group having a C 7-11 backbone, optionally branched with a C 1-6 alkyl group at any C position in the backbone, or a pharmaceutically acceptable salt, amide or ester thereof, wherein the backbone of the alkyl or alkenyl group, and/or the branched alkyl groups, are optionally interrupted by one or more heteroatoms, provided that when R1 is an alkyl group having a C 7 backbone, the branching does not consist only of a hexyl group at the a carbon of R1, or only of a methyl group at the γ carbon of R1, or of only single methyl groups at both the β and ω−1 carbons of R1, and provided that when R1 is an alkyl group having a C 8 or C 11 backbone, the branching does not consist only of a propyl group at the a carbon of R1, for use in the treatment or prevention of a disease or a biomedical condition selected from seizure-related disorders, bipolar disorders, mania, depression, migraine, attention deficit hyperactivity disorders, latent HIV infection, Alzheimer's disease, chorea, schizophrenia, ischemia, cancer and fatal blood loss.
1. A method of treating epilepsy, the method comprising administering to a subject having epilepsy a therapeutically effective amount of decanoic acid wherein the therapeutically effective amount of decanoic acid is about 1 to 1500 μg/kg per dose.
2. The method of claim 1 , wherein the therapeutically effective amount of the decanoic acid is administered to the subject with one or more of a pharmaceutically acceptable carrier, a pharmaceutically acceptable adjuvant or a pharmaceutically acceptable vehicle.
3. The method of claim 1 , wherein the therapeutically effective amount of the decanoic acid is administered to the subject orally.